In a new job - May 19, 2017
Pharmalink appoints new Chief Executive Officer
Pharmalink has appointed Ms Aguiar-Lucander to lead the company’s expansion and strategic development. Aguiar-Lucander will, in conjunction with the Pharmalink team, pursue a range of initiatives, including raising private or public capital for the Phase 3 trial, expanding the company’s development platform, in-licensing of additional compounds as well as partnering. Pharmalink’s current CEO, Dr Johan […]
Clinical Trials - March 30, 2017
Positive results from Pharmalink trial
Pharmalink announces that positive results and analyses from the completed Phase 2b trial of its oral drug candidate Nefecon in primary IgA nephropathy (IgAN) patients have been published online in The Lancet. This is the first time the full results from this trial have been published in this format. In the paper, clinical data are […]
In a new job - January 10, 2017
Maria Carell joins the board of Pharmalink
Pharmalink AB, announces the election of Maria Carell as Chair of the company’s Board of Directors. Carell replaces Hilde Furberg as Chair, who is elected Vice Chair of the company’s Board of Directors. She has an extensive background in operating, acquiring and developing healthcare and life science companies. She has previously held the position as CEO […]
Clinical Trials - January 14, 2014
Pharmalink completes enrolment of patients into phase IIb clinical study
Pharmalink has completed recruitment of patients into a Phase IIb NEFIGAN study of its orphan drug product, Nefecon. Pharmalink expects to announce top-line results in mid-2015. The Phase IIb study is a multi-center, randomized, double-blinded placebo-controlled clinical trial designed to assess the efficacy and safety of two different doses of Nefecon in 90 IgA nephropathy […]
Drug Development Pharma - October 29, 2013
Pharmalink receives US orphan drug designation
Pharmalink receives US orphan drug designation for Busulipo, its novel oncology product for bone marrow transplantation. Busulipo is a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation). The company is currently preparing for registration trials with an optimized formulation of Busulipo as […]
Financing - October 4, 2013
Pharmalink raises SEK 96 million
The Swedish company Pharmalink has raised SEK 96 million to undertake pivotal studies with lead programs in cancer therapy and renal disease. Pharmalink, a specialty pharma company focused on orphan and niche products, today announces it has raised SEK96 million (€11m / US$15m) in a Series C financing round. The round was co-led by two […]
